These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 27373507)

  • 1. Nanobodies® as inhaled biotherapeutics for lung diseases.
    Van Heeke G; Allosery K; De Brabandere V; De Smedt T; Detalle L; de Fougerolles A
    Pharmacol Ther; 2017 Jan; 169():47-56. PubMed ID: 27373507
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Delivery of ALX-0171 by inhalation greatly reduces respiratory syncytial virus disease in newborn lambs.
    Larios Mora A; Detalle L; Gallup JM; Van Geelen A; Stohr T; Duprez L; Ackermann MR
    MAbs; 2018 Jul; 10(5):778-795. PubMed ID: 29733750
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nanobodies® specific for respiratory syncytial virus fusion protein protect against infection by inhibition of fusion.
    Schepens B; Ibañez LI; De Baets S; Hultberg A; Bogaert P; De Bleser P; Vervalle F; Verrips T; Melero J; Vandevelde W; Vanlandschoot P; Saelens X
    J Infect Dis; 2011 Dec; 204(11):1692-701. PubMed ID: 21998474
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhaled Heparin: Therapeutic Efficacy and Recent Formulations.
    Yildiz-Pekoz A; Ozsoy Y
    J Aerosol Med Pulm Drug Deliv; 2017 Jun; 30(3):143-156. PubMed ID: 28418758
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhaled Formulation Design for the Treatment of Lung Infections.
    Garcia-Contreras L; Yadav KS
    Curr Pharm Des; 2015; 21(27):3875-901. PubMed ID: 26290199
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral versus inhaled ribavirin therapy for respiratory syncytial virus infection after lung transplantation.
    Li L; Avery R; Budev M; Mossad S; Danziger-Isakov L
    J Heart Lung Transplant; 2012 Aug; 31(8):839-44. PubMed ID: 22621746
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel nanobody specific for respiratory surfactant protein A has potential for lung targeting.
    Wang SM; He X; Li N; Yu F; Hu Y; Wang LS; Zhang P; Du YK; Du SS; Yin ZF; Wei YR; Mulet X; Coia G; Weng D; He JH; Wu M; Li HP
    Int J Nanomedicine; 2015; 10():2857-69. PubMed ID: 25926731
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nanobody Conjugates for Targeted Cancer Therapy and Imaging.
    Kang W; Ding C; Zheng D; Ma X; Yi L; Tong X; Wu C; Xue C; Yu Y; Zhou Q
    Technol Cancer Res Treat; 2021; 20():15330338211010117. PubMed ID: 33929911
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The development of nanobodies for therapeutic applications.
    Van Bockstaele F; Holz JB; Revets H
    Curr Opin Investig Drugs; 2009 Nov; 10(11):1212-24. PubMed ID: 19876789
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advances in the pulmonary delivery of poorly water-soluble drugs: influence of solubilization on pharmacokinetic properties.
    Tolman JA; Williams RO
    Drug Dev Ind Pharm; 2010 Jan; 36(1):1-30. PubMed ID: 19640248
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Strategies for overcoming the biological barriers associated with the administration of inhaled monoclonal antibodies for lung diseases.
    Matera MG; Calzetta L; Rinaldi B; Cazzola M; Rogliani P
    Expert Opin Drug Deliv; 2023; 20(8):1085-1095. PubMed ID: 37715502
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of pulmonary diseases on the fate of inhaled medicines--a review.
    Wang YB; Watts AB; Peters JI; Williams RO
    Int J Pharm; 2014 Jan; 461(1-2):112-28. PubMed ID: 24291124
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Delivering drugs to the lungs: The history of repurposing in the treatment of respiratory diseases.
    Newman SP
    Adv Drug Deliv Rev; 2018 Aug; 133():5-18. PubMed ID: 29653129
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nanobodies as novel agents for disease diagnosis and therapy.
    Siontorou CG
    Int J Nanomedicine; 2013; 8():4215-27. PubMed ID: 24204148
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patented therapeutic drug delivery strategies for targeting pulmonary diseases.
    Thakur AK; Chellappan DK; Dua K; Mehta M; Satija S; Singh I
    Expert Opin Ther Pat; 2020 May; 30(5):375-387. PubMed ID: 32178542
    [No Abstract]   [Full Text] [Related]  

  • 16. Insights on animal models to investigate inhalation therapy: Relevance for biotherapeutics.
    Guillon A; Sécher T; Dailey LA; Vecellio L; de Monte M; Si-Tahar M; Diot P; Page CP; Heuzé-Vourc'h N
    Int J Pharm; 2018 Jan; 536(1):116-126. PubMed ID: 29180257
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adaptive Aerosol Delivery (AAD) technology.
    Denyer J; Nikander K; Smith NJ
    Expert Opin Drug Deliv; 2004 Nov; 1(1):165-76. PubMed ID: 16296727
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nanotechnology approaches for inhalation treatment of lung diseases.
    Kuzmov A; Minko T
    J Control Release; 2015 Dec; 219():500-518. PubMed ID: 26297206
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systemic delivery of biotherapeutics through the lung: opportunities and challenges for improved lung absorption.
    Sakagami M
    Ther Deliv; 2013 Dec; 4(12):1511-25. PubMed ID: 24304249
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nanobodies and their Use in GPCR Drug Discovery.
    Cromie KD; Van Heeke G; Boutton C
    Curr Top Med Chem; 2015; 15(24):2543-57. PubMed ID: 26126902
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.